zanubrutinib + obinutuzumab

Zanubrutinib + obinutuzumab is a fixed-dose combination of two agents used for the treatment of relapsed or refractory follicular lymphoma in adults who have received at least two prior lines of therapy. Zanubrutinib is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK), which blocks B-cell receptor signaling, thereby inhibiting proliferation and survival of malignant B cells. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody that induces direct cell death and enhances antibody-dependent cellular cytotoxicity against CD20-expressing B cells. The combination has demonstrated superior efficacy compared to obinutuzumab alone, with higher overall response rates and longer progression-free survival, as shown in the phase 2 ROSEWOOD trial[2][3][5]. The regimen was granted accelerated FDA approval in March 2024 for relapsed/refractory follicular lymphoma[1][2][5].

Other names

ZO